NURIX THERAPEUTICS, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
NURIX THERAPEUTICS, INC. (NRIX) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of -$11.13 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-05-31 was -$15.25M.
- NURIX THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-02-28 was $4.12M, a 40.63% decline year-over-year.
- NURIX THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-11-30 was $11.04M, a 22.36% increase year-over-year.
- NURIX THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-08-31 was $6.34M, a 4.94% increase year-over-year.
- NURIX THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $17.31M, a 46.50% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was $11.82M, a 278.35% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was $3.12M, a 58.28% decline from fiscal 2022.
- NURIX THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was $7.49M, a 20.38% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-05-31 | -$15.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | -$11.13M 10-Q · filed 2026-07-09 | -$92.00K derived: sum of 3 quarters · filed 2026-07-09 | $6.24M derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2026-02-28 | $4.12M 10-Q · filed 2026-04-08 | $15.16M derived: sum of 2 quarters · filed 2026-04-08 | $21.50M derived: sum of 3 quarters · filed 2026-04-08 | $14.49M derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2025-11-30 | $11.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $17.38M derived: sum of 2 quarters · filed 2026-01-28 | $10.37M derived: sum of 3 quarters · filed 2026-07-09 | $17.31M 10-K · filed 2026-01-28 | |||
| 2025-08-31 | $6.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$670.00K derived: sum of 2 quarters · filed 2026-07-09 | $6.27M 10-Q · filed 2025-10-09 | $15.29M derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2025-05-31 | -$7.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | -$68.00K 10-Q · filed 2026-07-09 | $8.96M derived: sum of 3 quarters · filed 2026-07-09 | $14.99M derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2025-02-28 | $6.94M 10-Q · filed 2026-04-08 | $15.96M derived: sum of 2 quarters · filed 2026-04-08 | $22.00M derived: sum of 3 quarters · filed 2026-04-08 | $15.16M derived: sum of 4 quarters · filed 2026-04-08 | |||
| 2024-11-30 | $9.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $15.06M derived: sum of 2 quarters · filed 2026-01-28 | $8.22M derived: sum of 3 quarters · filed 2026-01-28 | $11.82M 10-K · filed 2026-01-28 | |||
| 2024-08-31 | $6.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$801.00K derived: sum of 2 quarters · filed 2025-10-09 | $2.79M 10-Q · filed 2025-10-09 | $5.87M derived: sum of 4 quarters · filed 2026-01-28 | |||
| 2024-05-31 | -$6.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | -$3.25M 10-Q · filed 2025-07-09 | -$171.00K derived: sum of 3 quarters · filed 2026-01-28 | $4.52M derived: sum of 4 quarters · filed 2026-01-28 | |||
| 2024-02-29 | $3.59M 10-Q · filed 2025-04-08 | $6.67M derived: sum of 2 quarters · filed 2026-01-28 | $11.36M derived: sum of 3 quarters · filed 2026-01-28 | $13.62M derived: sum of 4 quarters · filed 2026-01-28 | |||
| 2023-11-30 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $7.77M derived: sum of 2 quarters · filed 2026-01-28 | $10.03M derived: sum of 3 quarters · filed 2026-01-28 | $3.12M 10-K · filed 2026-01-28 | |||
| 2023-08-31 | $4.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $6.95M derived: sum of 2 quarters · filed 2024-10-11 | $48.00K 10-Q · filed 2024-10-11 | $3.34M derived: sum of 4 quarters · filed 2025-01-28 | |||
| 2023-05-31 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | -$4.65M 10-Q · filed 2024-07-11 | -$1.35M derived: sum of 3 quarters · filed 2025-01-28 | $14.00K derived: sum of 4 quarters · filed 2025-01-28 | |||
| 2023-02-28 | -$6.91M 10-Q · filed 2024-04-10 | -$3.61M derived: sum of 2 quarters · filed 2025-01-28 | -$2.24M derived: sum of 3 quarters · filed 2025-01-28 | $3.90M derived: sum of 4 quarters · filed 2025-01-28 | |||
| 2022-11-30 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $4.66M derived: sum of 2 quarters · filed 2025-01-28 | $10.80M derived: sum of 3 quarters · filed 2025-01-28 | $7.49M 10-K · filed 2025-01-28 | |||
| 2022-08-31 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $7.51M derived: sum of 2 quarters · filed 2023-10-12 | $4.19M 10-Q · filed 2023-10-12 | $7.57M derived: sum of 4 quarters · filed 2023-10-12 | |||
| 2022-05-31 | $6.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $2.82M 10-Q · filed 2023-07-13 | $6.21M derived: sum of 3 quarters · filed 2023-07-13 | $9.73M derived: sum of 4 quarters · filed 2023-07-13 | |||
| 2022-02-28 | -$3.32M 10-Q · filed 2023-04-13 | $63.00K derived: sum of 2 quarters · filed 2023-04-13 | $3.59M derived: sum of 3 quarters · filed 2023-04-13 | $731.00K derived: sum of 4 quarters · filed 2023-04-13 | |||
| 2021-11-30 | $3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $6.91M derived: sum of 2 quarters · filed 2023-02-09 | $4.05M derived: sum of 3 quarters · filed 2023-02-09 | $6.22M 10-K · filed 2023-02-09 | |||
| 2021-08-31 | $3.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $668.00K derived: sum of 2 quarters · filed 2022-10-06 | $2.84M 10-Q · filed 2022-10-06 | $2.84M 10-Q · filed 2021-10-14 | $4.54M derived: sum of 4 quarters · filed 2022-10-06 | ||
| 2021-05-31 | -$2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | -$692.00K 10-Q · filed 2022-07-07 | -$671.00K 10-Q · filed 2021-07-13 | $1.01M derived: sum of 3 quarters · filed 2022-07-07 | $3.48M derived: sum of 4 quarters · filed 2022-07-07 | ||
| 2021-02-28 | $2.17M 10-Q · filed 2022-04-08 | $2.17M 10-Q · filed 2021-04-13 | $3.87M derived: sum of 2 quarters · filed 2022-04-08 | $6.34M derived: sum of 3 quarters · filed 2022-04-08 | $3.02M derived: sum of 4 quarters · filed 2022-04-08 | ||
| 2020-11-30 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $4.17M derived: sum of 2 quarters · filed 2022-01-28 | $851.00K derived: sum of 3 quarters · filed 2022-01-28 | $2.28M 10-K · filed 2022-01-28 | |||
| 2020-08-31 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | -$852.00K derived: sum of 2 quarters · filed 2021-10-14 | $579.00K 10-Q · filed 2021-10-14 | $2.19M derived: sum of 4 quarters · filed 2022-01-28 | |||
| 2020-05-31 | -$3.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | -$1.89M 10-Q · filed 2021-07-13 | -$279.00K derived: sum of 3 quarters · filed 2022-01-28 | ||||
| 2020-02-29 | $1.43M 10-Q · filed 2021-04-13 | $3.04M derived: sum of 2 quarters · filed 2022-01-28 | |||||
| 2019-11-30 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $2.37M 10-K · filed 2022-01-28 | |||||
| 2019-08-31 | $767.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |